Abstract
To investigate the theoretical model of the three-dimensional structure of multidrug resistance protein 1(P-glycoprotein, expressed by MDR1 gene of E. histolytica) and its molecular docking with anti-amoebic agents. The theoretical model of multidrug resistance protein 1(P-glyoprotein, expressed by MDR1 gene of E. histolytica) was predicted by homology modeling on the structure of the 3G61. Docking studies were performed to investigate the interaction of p-glycoprotein with antiamoebic gents. MRPEH1F is significant model for p-glycoprotein and have total of 114 amino acid residues. The model is well supported by cross validation data generated after analyzing criss-cross residues, local geometry check as well as ramachandran plot. Molecular docking of MRPEH1F revealed that all the test molecules have strong binding affinity along with significant interactions. Henceforth, none of the molecules will probably be effective for the multidrug resistant strains of E. histolytica.
Keywords: 2-Pyrazolines, Entamoeba histolytica, Homology modeling, MDR1 gene, Molecular docking.
Current Topics in Medicinal Chemistry
Title:Homology Modeling of MDR1 Gene MDR1_ENTHI of E. histolytica & its Molecular Docking with Anti-Entamoeba Histolytica Agents
Volume: 15 Issue: 11
Author(s): Rajeev K. Singla
Affiliation:
Keywords: 2-Pyrazolines, Entamoeba histolytica, Homology modeling, MDR1 gene, Molecular docking.
Abstract: To investigate the theoretical model of the three-dimensional structure of multidrug resistance protein 1(P-glycoprotein, expressed by MDR1 gene of E. histolytica) and its molecular docking with anti-amoebic agents. The theoretical model of multidrug resistance protein 1(P-glyoprotein, expressed by MDR1 gene of E. histolytica) was predicted by homology modeling on the structure of the 3G61. Docking studies were performed to investigate the interaction of p-glycoprotein with antiamoebic gents. MRPEH1F is significant model for p-glycoprotein and have total of 114 amino acid residues. The model is well supported by cross validation data generated after analyzing criss-cross residues, local geometry check as well as ramachandran plot. Molecular docking of MRPEH1F revealed that all the test molecules have strong binding affinity along with significant interactions. Henceforth, none of the molecules will probably be effective for the multidrug resistant strains of E. histolytica.
Export Options
About this article
Cite this article as:
Singla K. Rajeev, Homology Modeling of MDR1 Gene MDR1_ENTHI of E. histolytica & its Molecular Docking with Anti-Entamoeba Histolytica Agents, Current Topics in Medicinal Chemistry 2015; 15 (11) . https://dx.doi.org/10.2174/1568026615666150317222927
DOI https://dx.doi.org/10.2174/1568026615666150317222927 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum- Induced Peripheral Neurotoxicity
Current Cancer Drug Targets New Therapeutic Strategies for Castration-Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Current Medicinal Chemistry Doxycycline in Mitochondrial Mediated Pathway of Apoptosis: A Systematic Review
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Effects of Fisetin in Alzheimer’s and Parkinson’s Diseases: From Chemistry to Medicine
Current Topics in Medicinal Chemistry Synthesis and Antioxidant Activities of Ferrocenyl-containing Curcumin Analogues
Letters in Drug Design & Discovery The PYRIN Domain in Signal Transduction
Current Protein & Peptide Science Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Cancer-Homing Toxins
Current Pharmaceutical Design Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Continuous Nanostructures for the Controlled Release of Drugs
Current Pharmaceutical Design The CXCR4/SDF-1 Chemokine Axis: A Potential Therapeutic Target for Bone Metastases?
Current Pharmaceutical Design Characterization of YY1 OPB Peptide for its Anticancer Activity
Current Cancer Drug Targets Pomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers
Current Clinical Pharmacology Endoplasmic Reticulum Stress in Chronic Obstructive Lung Diseases
Current Molecular Medicine Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Resveratrol and Prostate Cancer: The Power of Phytochemicals
Current Medicinal Chemistry Bioinformatics Approaches for Anti-cancer Drug Discovery
Current Drug Targets Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets